$CTMX
CytomX Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000095017021000946 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $17.59M $16.29M $16.61M
YoY Change -1.13% -1.93% 84.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.09M $9.393M $8.680M
YoY Change 28.45% 8.21% -7.76%
% of Gross Profit
Research & Development $29.14M $26.10M $24.07M
YoY Change 21.18% 8.45% -21.95%
% of Gross Profit
Depreciation & Amortization $680.0K $751.0K $700.0K
YoY Change 13.33% 7.29% 0.0%
% of Gross Profit
Operating Expenses $40.23M $35.49M $32.75M
YoY Change 23.09% 8.39% -18.64%
Operating Profit -$22.64M -$19.21M -$16.14M
YoY Change 52.0% 19.0% -48.33%
Interest Expense $70.00K $44.00K $450.0K
YoY Change -65.0% -90.22% -80.93%
% of Operating Profit
Other Income/Expense, Net -$13.00K -$82.00K $5.000K
YoY Change -13.33% -1740.0% -105.56%
Pretax Income -$22.58M -$19.24M -$15.68M
YoY Change 53.53% 22.73% -45.86%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$22.58M -$19.24M -$15.68M
YoY Change 53.53% 22.73% -45.86%
Net Earnings / Revenue -128.41% -118.14% -94.41%
Basic Earnings Per Share
Diluted Earnings Per Share -$346.3K -$295.8K -$340.4K
COMMON SHARES
Basic Shares Outstanding 65.16M 65.06M 45.92M
Diluted Shares Outstanding 65.21M 65.06M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $236.3M $266.2M $346.4M
YoY Change -26.41% -23.16% -0.79%
Cash & Equivalents $236.3M $256.1M $291.4M
Short-Term Investments $5.000K $10.03M $55.00M
Other Short-Term Assets $3.822M $3.897M $6.900M
YoY Change -31.75% -43.52% -8.0%
Inventory
Prepaid Expenses
Receivables $887.0K $931.0K $200.0K
Other Receivables $0.00 $0.00 $13.10M
Total Short-Term Assets $241.0M $271.0M $366.6M
YoY Change -29.18% -26.08% -0.02%
LONG-TERM ASSETS
Property, Plant & Equipment $6.271M $6.699M $31.40M
YoY Change -79.37% -78.67% 333.82%
Goodwill $949.0K $949.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments $99.97M $99.91M
YoY Change
Other Assets $902.0K $901.0K $2.300M
YoY Change -60.78% -60.83% 67.27%
Total Long-Term Assets $130.2M $131.4M $35.90M
YoY Change 273.17% 266.11% -7.01%
TOTAL ASSETS
Total Short-Term Assets $241.0M $271.0M $366.6M
Total Long-Term Assets $130.2M $131.4M $35.90M
Total Assets $371.2M $402.4M $402.5M
YoY Change -1.06% -0.01% -0.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.516M $1.755M $4.900M
YoY Change -57.89% -64.18% 8.41%
Accrued Expenses $25.17M $19.25M $21.15M
YoY Change 5.1% -8.96% -5.88%
Deferred Revenue $73.09M $72.37M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $99.77M $93.38M $98.80M
YoY Change -2.18% -5.49% 25.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $159.8M $178.1M $244.9M
YoY Change -29.02% -27.27% 25330.94%
Total Long-Term Liabilities $159.8M $178.1M $244.9M
YoY Change -29.02% -27.27% 25330.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.77M $93.38M $98.80M
Total Long-Term Liabilities $159.8M $178.1M $244.9M
Total Liabilities $259.6M $271.5M $343.7M
YoY Change -20.65% -21.01% 13.14%
SHAREHOLDERS EQUITY
Retained Earnings -$507.5M -$484.9M
YoY Change
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $111.7M $131.0M $58.83M
YoY Change
Total Liabilities & Shareholders Equity $371.2M $402.4M $402.5M
YoY Change -1.06% -0.01% -0.69%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$22.58M -$19.24M -$15.68M
YoY Change 53.53% 22.73% -45.86%
Depreciation, Depletion And Amortization $680.0K $751.0K $700.0K
YoY Change 13.33% 7.29% 0.0%
Cash From Operating Activities -$29.70M -$28.24M $97.10M
YoY Change 20.24% -129.08% -299.38%
INVESTING ACTIVITIES
Capital Expenditures -$268.0K -$96.00K -$100.0K
YoY Change -66.5% -4.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities $10.00M -$45.90M $49.50M
YoY Change -111.2% -192.74% 578.08%
Cash From Investing Activities $9.734M -$46.00M $49.50M
YoY Change -110.8% -192.93% 617.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 104.0K 726.0K 1.500M
YoY Change -48.0% -51.6% 114.29%
NET CHANGE
Cash From Operating Activities -29.70M -28.24M 97.10M
Cash From Investing Activities 9.734M -46.00M 49.50M
Cash From Financing Activities 104.0K 726.0K 1.500M
Net Change In Cash -19.86M -73.51M 148.1M
YoY Change -82.67% -149.64% -460.34%
FREE CASH FLOW
Cash From Operating Activities -$29.70M -$28.24M $97.10M
Capital Expenditures -$268.0K -$96.00K -$100.0K
Free Cash Flow -$29.43M -$28.14M $97.20M
YoY Change 23.15% -128.95% -301.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001501989
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37587
dei Entity Registrant Name
EntityRegistrantName
CytomX Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3521219
dei Entity Address Address Line1
EntityAddressAddressLine1
151 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
515-3185
dei Security12b Title
Security12bTitle
Common Stock, $0.00001 par value per share
dei Trading Symbol
TradingSymbol
CTMX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19253000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23059000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
72369000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
74869000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65157003
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
256146000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10031000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
124260000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
931000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
798000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3897000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7096000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
271005000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
324013000
CY2021Q2 us-gaap Long Term Investments
LongTermInvestments
99914000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6699000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6950000
CY2021Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1094000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1167000
CY2021Q2 us-gaap Goodwill
Goodwill
949000
CY2020Q4 us-gaap Goodwill
Goodwill
949000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20961000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22495000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
901000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2172000
CY2021Q2 us-gaap Assets
Assets
402440000
CY2020Q4 us-gaap Assets
Assets
358663000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1755000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2996000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
93377000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
100924000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
158189000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
186261000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19921000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21675000
CY2021Q2 us-gaap Liabilities
Liabilities
271487000
CY2020Q4 us-gaap Liabilities
Liabilities
308860000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65157003
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65157003
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48251819
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48251819
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
615849000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
499964000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-484912000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-450115000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130953000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
402440000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358663000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16288000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16608000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32259000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66201000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26100000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24066000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48472000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66880000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9393000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8680000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18619000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18252000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
35493000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
32746000
us-gaap Operating Expenses
OperatingExpenses
67091000
us-gaap Operating Expenses
OperatingExpenses
85132000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19205000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16138000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34832000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18931000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
454000
us-gaap Investment Income Interest
InvestmentIncomeInterest
112000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1530000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-82000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19243000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15679000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34797000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17385000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13911000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15679000
us-gaap Net Income Loss
NetIncomeLoss
-34797000
us-gaap Net Income Loss
NetIncomeLoss
-3474000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.30
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.34
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.55
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.08
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65055998
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46057063
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63023349
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45890510
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-320000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
62000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-41000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19185000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15999000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34735000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3515000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
49803000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107712000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1023000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15554000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
146022000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
173000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
518000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3425000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
58000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-19243000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130953000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51113000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2157000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4013000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
279000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
12205000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
69767000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1179000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
369000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3513000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-320000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-15679000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
58829000
us-gaap Profit Loss
ProfitLoss
-34797000
us-gaap Profit Loss
ProfitLoss
-3474000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
72000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1278000
ctmx Depreciation And Amortization Excluding Amortization Of Intangible Assets
DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
1187000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-281000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
314000
us-gaap Share Based Compensation
ShareBasedCompensation
6459000
us-gaap Share Based Compensation
ShareBasedCompensation
7526000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-1534000
ctmx Noncash Lease Expense
NoncashLeaseExpense
-1415000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
133000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
193000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3199000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12782000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1271000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-636000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1173000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
579000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-5559000
ctmx Increase Decrease In Accrued And Other Liabilities Noncurrent
IncreaseDecreaseInAccruedAndOtherLiabilitiesNoncurrent
-11302000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-30572000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
64014000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58139000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
47364000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1096000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1086000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
99898000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
44707000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
113994000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
97687000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51894000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107712000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1714000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3705000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109426000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3705000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
64287000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
102963000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
257063000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
292305000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
54000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
618000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Description of the Business</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CytomX Therapeutics, Inc. (the “Company”) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The Company aims to build a commercial enterprise to maximize its impact on the treatment of cancer. The Company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
256146000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191859000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
291388000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188425000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
917000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
257063000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192776000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
292305000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189342000
CY2021Q2 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
7099000
CY2020Q4 ctmx Accrued Research And Clinical Current
AccruedResearchAndClinicalCurrent
10092000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5797000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8362000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2029000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
815000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3402000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
926000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
595000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19253000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23059000
CY2021Q2 us-gaap Revenues
Revenues
16288000
CY2020Q2 us-gaap Revenues
Revenues
16608000
us-gaap Revenues
Revenues
32259000
us-gaap Revenues
Revenues
66201000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
261130000
ctmx Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
30572000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
230558000
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
230600000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10929530
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3633597
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.80
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
391478
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2155707
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.20
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12015942
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.05
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5735023
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.92
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3425000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3513000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6459000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7526000
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2500000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1273000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1239000
us-gaap Operating Lease Payments
OperatingLeasePayments
2547000
us-gaap Operating Lease Payments
OperatingLeasePayments
2478000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20961000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22495000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3402000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3195000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19921000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21675000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23323000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24870000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y9M
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2582000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5273000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5420000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5572000
CY2021Q2 ctmx Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
10117000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28964000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5641000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
23323000
CY2020Q1 ctmx Net Operating Loss Carryback Period
NetOperatingLossCarrybackPeriod
P5Y
CY2020Q1 ctmx Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation
PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation
0.80

Files In Submission

Name View Source Status
0000950170-21-000946-index-headers.html Edgar Link pending
0000950170-21-000946-index.html Edgar Link pending
0000950170-21-000946.txt Edgar Link pending
0000950170-21-000946-xbrl.zip Edgar Link pending
ctmx-20210630.htm Edgar Link pending
ctmx-20210630.xsd Edgar Link pending
ctmx-20210630ex31_1.htm Edgar Link pending
ctmx-20210630ex31_2.htm Edgar Link pending
ctmx-20210630ex32_1.htm Edgar Link pending
ctmx-20210630ex32_2.htm Edgar Link pending
ctmx-20210630_cal.xml Edgar Link unprocessable
ctmx-20210630_def.xml Edgar Link unprocessable
ctmx-20210630_htm.xml Edgar Link completed
ctmx-20210630_lab.xml Edgar Link unprocessable
ctmx-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending